Imatinib (DB00619): A Comprehensive Monograph on the Archetypal Tyrosine Kinase Inhibitor

Section 1: Introduction: The Dawn of Targeted Cancer Therapy

1.1. Imatinib as a Paradigm Shift in Oncology

Imatinib is a small molecule kinase inhibitor that represents a watershed moment in the history of medicine and oncology. Its introduction in 2001 fundamentally altered the treatment of cancer, most notably Chronic Myeloid Leukemia (CML).[1] The drug's unprecedented clinical success led to it being hailed as a "miracle drug" and a "magical bullet," as it transformed CML from a rapidly fatal disease into a manageable, chronic condition for the majority of patients.[1]

Beyond its therapeutic impact, the development and success of imatinib established and validated a new paradigm in drug development known as "targeted therapy".[1] This approach moves away from the indiscriminate cytotoxicity of traditional chemotherapy and toward treatments tailored to the specific genetic and molecular abnormalities driving an individual patient's cancer.[1] Imatinib proved that by identifying a critical oncogenic driver and designing a drug to specifically inhibit it, remarkable efficacy could be achieved with a more manageable toxicity profile. This principle has since become the cornerstone of modern precision oncology, guiding the development of hundreds of subsequent targeted agents.

1.2. Historical Development and Discovery: A Story of Rational Drug Design

The story of imatinib is a testament to the power of rational drug design, built upon decades of fundamental scientific discovery. The narrative began in 1960 with the identification of an abnormally small chromosome 22 in patients with CML, an alteration that became known as the Philadelphia (Ph) chromosome.[5] Years later, this was understood to be the result of a reciprocal translocation between chromosomes 9 and 22, denoted as

t(9;22).[6] This breakthrough provided a specific, disease-defining genetic marker.

Subsequent research revealed that this translocation results in the molecular juxtaposition of the Breakpoint Cluster Region (BCR) gene on chromosome 22 and the Abelson murine leukemia viral oncogene homolog 1 (ABL1) gene on chromosome 9.[6] The product of this aberrant gene is a chimeric oncoprotein known as Bcr-Abl.[6] Critically, the Bcr-Abl protein is a constitutively active tyrosine kinase, meaning it is perpetually "switched on," driving uncontrolled cell proliferation and inhibiting apoptosis—the key pathogenetic events in CML.[6] The discovery of this single, causative molecular abnormality provided the ideal target for a rational drug discovery program.

In the early 1990s, a team at the pharmaceutical company Ciba-Geigy (a predecessor of Novartis), led by biochemist Nicholas Lyndon, began a concerted effort to screen for and develop a compound that could specifically inhibit the ATP-binding site of the Abl kinase.[3] After synthesizing and testing numerous 2-phenylaminopyrimidine derivatives, one candidate compound, STI-571, emerged as a potent and specific Bcr-Abl inhibitor.[5] The clinical development of this compound was championed by Dr. Brian Druker, an oncologist at the Dana-Farber Cancer Institute, who recognized its immense potential and drove it forward into human trials.[3] This linear, target-driven pathway—from identifying a genetic marker to understanding its protein product and then designing a drug to inhibit it—became the blueprint for a new generation of cancer therapies.

1.3. Key Regulatory Milestones and Global Approvals

The first Phase I clinical trial of imatinib (then STI-571) commenced in June 1998.[5] The results were immediate and extraordinary. Between September 1998 and April 1999, investigators observed that nearly every CML patient treated with the drug experienced a significant and rapid response.[5] These remarkable findings, presented at the American Society of Hematology meeting in December 1999, galvanized the medical community and the manufacturer.[5]

Recognizing the drug's transformative potential, the U.S. Food and Drug Administration (FDA) granted it a fast-track designation, particularly for patients with advanced CML for whom few effective and well-tolerated treatments existed.[5] Novartis committed unprecedented resources to accelerate its development. Following the submission of a New Drug Application (NDA), the FDA approved Gleevec in a record-breaking 10 weeks, marking the fastest review period for any cancer drug at that time.[5] The initial FDA approval was granted on May 10, 2001, for the treatment of CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.[3] This was quickly followed by approval from the European Medicines Agency (EMA) on November 7, 2001.[1] Over the subsequent years, the indications for imatinib were progressively expanded to include first-line CML treatment, various other leukemias, and solid tumors, with new formulations also gaining approval.[5]

Section 2: Physicochemical Profile and Formulation

2.1. Chemical Identification and Nomenclature

Imatinib is a well-characterized small molecule drug with multiple identifiers used across scientific and regulatory databases. The clinically administered form is the mesylate salt, which has different properties and identifiers from the free base.

• Drug Name: Imatinib [1]
• DrugBank ID: DB00619 [1]
• CAS Number: 152459-95-5 (free base); 220127-57-1 (mesylate salt) [1]
• IUPAC Name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide [1]
• Synonyms and Code Names: Common synonyms and development codes include Gleevec, Glivec, Imkeldi, STI-571, and CGP 57148.[10]
• Other Identifiers: The compound is extensively cataloged in chemical and biological databases, including ChEBI (CHEBI:45783), ChEMBL (CHEMBL941), and KEGG (D08066).[1]

2.2. Molecular Structure, Formula, and Properties

Imatinib is a synthetic organic compound classified as a 2-phenylaminopyrimidine derivative.[17] Its complex structure incorporates several key chemical moieties, including pyridine, pyrimidine, benzamide, and N-methylpiperazine groups, which contribute to its binding affinity and pharmacokinetic properties.[1] It is obtained by the formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine.[19]

• Molecular Formula:
• Free Base: C29​H31​N7​O [1]
• Mesylate Salt: C29​H31​N7​O⋅CH4​SO3​ [8]
• Molecular Weight:
• Free Base: Average weight is approximately 493.6 g/mol; monoisotopic mass is 493.259 g/mol.[12]
• Mesylate Salt: The molecular weight is 589.7 g/mol.[13]
• Physicochemical Properties: Imatinib possesses 2 hydrogen bond donors, 8 hydrogen bond acceptors, and 8 rotatable bonds, with a topological polar surface area of 86.28 A˚2.[24] These properties contribute to its favorable "druglikeness," as it does not violate any of Lipinski's Rule-of-Five criteria for oral bioavailability.[24]

2.3. Formulation and Physical Characteristics

The decision to develop the mesylate salt was a critical step in creating a viable drug product. This salt form possesses superior physicochemical properties for oral administration compared to the free base.

• Appearance: Imatinib mesylate is a white to off-white, or sometimes brownish or yellowish tinged, crystalline powder.[8]
• Solubility: The mesylate salt exhibits pH-dependent solubility. It is very soluble in water and in aqueous buffers at an acidic pH (≤ 5.5) but is only very slightly soluble to insoluble in neutral or alkaline aqueous buffers.[8] This high solubility in acidic conditions facilitates its dissolution in the stomach. It is also soluble in DMSO but poorly soluble in ethanol.[8] This solubility profile was essential for developing a formulation with consistent and high oral bioavailability.
• Formulations: Imatinib is commercially available as film-coated oral tablets in 100 mg and 400 mg strengths.[17] In 2024, a strawberry-flavored oral liquid formulation, Imkeldi, was approved, providing a convenient alternative for pediatric patients or adults who have difficulty swallowing tablets, and allowing for more precise dosing based on body surface area.[11]

Table 2.1: Key Chemical Identifiers and Properties of Imatinib
Property	Imatinib (Free Base)	Imatinib Mesylate
DrugBank ID	DB00619 12	DB00619 (active moiety)
CAS Number	152459-95-5 1	220127-57-1 13
Molecular Formula	C29​H31​N7​O 1	C29​H31​N7​O⋅CH4​SO3​ 8
Molecular Weight (Average)	493.62 g/mol 20	589.71 g/mol 13
IUPAC Name	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide 1	N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate 13
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 1	O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=CC=C(CN5CCN(C)CC5)C=C4.CS(=O)(O)=O 13
InChIKey	KTUFNOKKBVMGRW-UHFFFAOYSA-N 1	YLMAHDNUQAMNNX-UHFFFAOYSA-N 13
Key Solubilities	Poorly soluble in water	Very soluble in water; soluble in DMSO 8

Section 3: Comprehensive Pharmacological Profile

3.1. Mechanism of Action: Selective Inhibition of Pathogenic Kinases

Imatinib is classified as a Type-2 protein-tyrosine kinase inhibitor, a class of drugs that binds to the inactive conformation of the kinase domain.[7] It functions as a competitive inhibitor of adenosine triphosphate (ATP) by occupying the ATP-binding pocket of its target kinases.[17] This binding action prevents the enzyme from transferring a terminal phosphate group from ATP to tyrosine residues on its protein substrates (phosphorylation). By blocking this critical step, imatinib effectively shuts down the downstream signaling cascades that regulate fundamental cellular processes, including proliferation, survival, and differentiation, ultimately leading to cell death in cancer cells dependent on these pathways.[22]

3.1.1. Primary Target: The Bcr-Abl Fusion Protein

The primary and most renowned target of imatinib is the Bcr-Abl tyrosine kinase, the constitutively active oncoprotein that is the hallmark of CML and a subset of Acute Lymphoblastic Leukemia (ALL).[6] Imatinib exhibits high potency and selectivity for Bcr-Abl.[7] It binds to a pocket on the Bcr-Abl kinase domain that is accessible only when the enzyme is in its inactive, non-functional conformation, thereby stabilizing this state and preventing its activation.[7] This blockade of Bcr-Abl activity halts the transmission of aberrant proliferative signals to the nucleus and induces apoptosis (programmed cell death) specifically in the malignant, Philadelphia chromosome-positive cells, while having minimal effect on normal, healthy cells that do not express this fusion protein.[6]

3.1.2. Inhibition of c-KIT and Platelet-Derived Growth Factor Receptors (PDGFR)

While designed to target Bcr-Abl, imatinib was discovered to be a potent inhibitor of several other key receptor tyrosine kinases. This broader activity profile is not a collection of unwanted side effects but is central to its efficacy in other malignancies. Imatinib potently inhibits the stem cell factor (SCF) receptor, known as c-KIT, and both alpha and beta platelet-derived growth factor receptors (PDGFR).[6]

This mechanism is the basis for its dramatic efficacy in Gastrointestinal Stromal Tumors (GIST), a majority of which are driven by gain-of-function mutations in the c−KIT gene that lead to its constitutive, ligand-independent activation.[6] Imatinib interrupts this aberrant KIT-mediated signaling, thereby inhibiting cell proliferation and inducing apoptosis in GIST cells.[6] Similarly, its activity against PDGFR explains its use in rare myelodysplastic/myeloproliferative diseases (MDS/MPD) that are characterized by genetic rearrangements involving the

PDGFR gene.[5] This demonstrates that the drug's utility is defined by its molecular targets rather than the specific anatomical site of the cancer.

3.1.3. Activity Against Other Kinase Targets

The inhibitory spectrum of imatinib extends to other kinases, including the RET proto-oncogene, Macrophage colony-stimulating factor 1 receptor (CSF1R), and Epithelial discoidin domain-containing receptor 1 (DDR1).[12] This wider range of targets may contribute to both its therapeutic effects and its side effect profile. Furthermore, preclinical research has uncovered novel activities for imatinib, suggesting potential for drug repurposing. It has been reported to block the fusion of SARS-CoV and MERS-CoV with host cells and to enhance the host macrophage response to

Mycobacterium tuberculosis, indicating potential applications in infectious diseases.[10]

3.2. Pharmacodynamics: Cellular and Systemic Effects

At the cellular level, the inhibition of Bcr-Abl, c-KIT, and PDGFR by imatinib disrupts a host of critical downstream signaling pathways that are hijacked by cancer cells. These include the Ras/MAPK pathway, which controls cellular proliferation; the Src/Pax/Fak/Rac pathway, which governs cellular motility and invasion; and the PI3K/AKT/BCL-2 pathway, a key regulator of apoptosis and cell survival.[12] By simultaneously blocking these pathways, imatinib delivers a multi-pronged attack on the cancer cell's core survival machinery.

The clinical pharmacodynamic effects are a direct reflection of this molecular action. In CML patients, a clear concentration-dependent decrease in white blood cell (WBC) counts is observed, providing a measurable indicator of drug activity.[32] A pharmacodynamic relationship has also been established between the steady-state plasma concentration of imatinib and the probability of developing edema, one of its most common side effects, highlighting the link between drug exposure and toxicity.[32]

3.3. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of imatinib is well-characterized and is highly favorable for a chronic oral therapy.

3.3.1. Absorption

Imatinib is rapidly and almost completely absorbed following oral administration, with a mean absolute bioavailability of 98%.[8] This high and consistent bioavailability is a key feature, ensuring reliable drug exposure with oral dosing. Peak plasma concentrations (

Cmax​) are typically reached within 2 to 4 hours after a dose.[8] While administration with a high-fat meal can slightly reduce the rate of absorption, it does not have a clinically significant effect on the overall extent of bioavailability.[29] It is recommended that imatinib be taken with a meal and a large glass of water to minimize the potential for gastrointestinal irritation.[26]

3.3.2. Distribution

Once absorbed into the bloodstream, imatinib is extensively bound to plasma proteins (approximately 95%), primarily to albumin and α1-acid glycoprotein.[25] This high degree of protein binding influences its distribution and clearance. With once-daily dosing, the drug accumulates to a steady state, with plasma concentrations increasing by 1.5- to 2.5-fold compared to the first dose.[12]

3.3.3. Metabolism

Imatinib undergoes extensive metabolism, predominantly in the liver, via the cytochrome P450 (CYP) enzyme system.[6] The major enzyme responsible for its biotransformation is

CYP3A4.[6] Other CYP isoforms, including CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play only a minor role in its metabolism.[6]

The primary metabolic pathway is N-demethylation of the piperazine moiety, which is mediated mainly by CYP3A4.[6] This process forms the main circulating metabolite, known as CGP 74588. This N-desmethyl derivative is pharmacologically active, with an

in vitro potency similar to that of the parent drug, imatinib.[6] However, its systemic exposure, as measured by the plasma area under the curve (AUC), is only about 15-16% of the parent drug's AUC, meaning imatinib itself is the primary contributor to the overall clinical effect.[8]

A critical aspect of imatinib's pharmacology is that it is not only a substrate of CYP3A4 but also a potent inhibitor of the enzyme.[32] Research has further defined it as a mechanism-based inhibitor, meaning it can irreversibly inactivate CYP3A4.[38] This dual role—where the drug inhibits its own primary clearance pathway—is a major contributor to the high inter-patient variability (around 40%) observed in its clearance and is the mechanistic basis for its extensive drug-drug interaction profile.[12]

3.3.4. Elimination

Imatinib and its metabolites are eliminated from the body primarily through biliary excretion into the feces. Within 7 days of an oral dose, approximately 68% is recovered in the feces and 13% in the urine, mostly in the form of metabolites.[25] The elimination half-life (

t1/2​) of the parent drug is approximately 18 hours, while the active metabolite (CGP 74588) has a longer half-life of about 40 hours.[7] The relatively long half-life of imatinib supports a convenient once-daily dosing schedule, which is beneficial for patient adherence in a chronic therapy setting.[7]

Table 3.1: Summary of Imatinib Pharmacokinetic Parameters
Parameter	Value / Description
Absolute Bioavailability	98% 8
Time to Peak Concentration (Tmax​)	2–4 hours 8
Plasma Protein Binding	~95% (mainly to albumin and α1-acid glycoprotein) 29
Primary Metabolic Enzyme	Cytochrome P450 3A4 (CYP3A4) 6
Active Metabolite	N-demethylated piperazine derivative (CGP 74588) 6
Elimination Half-life (t1/2​)	Parent Drug: ~18 hours; Active Metabolite: ~40 hours 7
Primary Route of Elimination	Fecal excretion (~68% of dose), primarily as metabolites 25

Section 4: Clinical Efficacy and Therapeutic Applications

4.1. FDA-Approved Indications: A Detailed Review

Imatinib mesylate is approved by the U.S. FDA for a wide range of hematologic malignancies and solid tumors, reflecting its activity against multiple kinase targets. Its utility is defined by the presence of specific molecular markers rather than by tumor histology alone, a principle that underpins its broad application.

The approved indications include:

• Chronic Myeloid Leukemia (CML):
• As a first-line treatment for newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive (Ph+) CML in the chronic phase.[5]
• For the treatment of Ph+ CML in more advanced stages, including blast crisis and accelerated phase, or in the chronic phase after the failure of prior interferon-alpha therapy.[12]
• Acute Lymphoblastic Leukemia (ALL):
• For adult patients with relapsed or refractory Ph+ ALL.[5]
• For newly diagnosed pediatric patients with Ph+ ALL, used in combination with chemotherapy.[5]
• Gastrointestinal Stromal Tumors (GIST):
• For the treatment of adult patients with unresectable and/or metastatic malignant GIST that are positive for the KIT (CD117) protein.[5]
• As an adjuvant therapy for adult patients following the complete surgical removal of KIT-positive GIST to help prevent recurrence.[5]
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD):
• For adult patients whose disease is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.[5]
• Aggressive Systemic Mastocytosis (ASM):
• For adult patients with ASM who do not have the D816V c-Kit mutation or whose c-Kit mutational status is unknown.[5]
• Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL):
• For adult patients with HES and/or CEL that are driven by the FIP1L1-PDGFRα fusion kinase.[5]
• Dermatofibrosarcoma Protuberans (DFSP):
• For adult patients with unresectable, recurrent, and/or metastatic DFSP, a rare skin tumor previously considered unresponsive to chemotherapy.[5]

4.2. Clinical Trial Evidence and Patient Outcomes

The clinical efficacy of imatinib is robustly supported by data from pivotal clinical trials that have redefined treatment standards.

• CML: The landmark International Randomized Study of Interferon and STI571 (IRIS) trial was instrumental in establishing imatinib as the standard of care for newly diagnosed CML. This study compared imatinib directly against the then-standard therapy of interferon-alpha plus low-dose cytarabine. The results were overwhelmingly in favor of imatinib. After 18 months of follow-up, the rate of major cytogenetic response was 87.1% in the imatinib arm versus 34.7% in the control arm. Even more impressively, the rate of complete cytogenetic response (CCyR)—a key marker of deep response—was 76% for imatinib versus only 15% for the interferon-based regimen.[7] This profound superiority led to the rapid adoption of imatinib as first-line therapy. Long-term follow-up has demonstrated a dramatic improvement in survival; the 5-year survival rate for CML has risen from 31% in the pre-imatinib era to over 70% by 2016 and is now approaching 90%.[14] For many patients who maintain a durable response, life expectancy is now similar to that of the general population.[14]
• GIST: Imatinib received its first FDA approval for advanced GIST in 2002, and this was expanded in 2012 to include adjuvant use after surgery to prevent tumor recurrence, based on trials showing a significant improvement in recurrence-free survival.[14]
• Other Indications: The approvals in other rare diseases were based on compelling data from smaller, often single-arm, Phase 2 studies. For instance, in relapsed/refractory Ph+ ALL, imatinib induced complete hematologic and cytogenetic responses in a significant subset of patients.[17] In ASM, it induced complete hematologic responses in 29% of patients in a pooled analysis of study and case report data.[17]

4.3. Off-Label and Investigational Uses

The mechanism-based action of imatinib has led to its exploration in various other conditions where its molecular targets are implicated. Off-label use, where a physician prescribes a drug for an unapproved indication, is common in oncology, especially for targeted therapies when a patient's tumor expresses the relevant molecular target.[4]

• Specific Off-Label Uses:
• Chordoma: Imatinib is used off-label, either as a single agent or in combination regimens, for the treatment of recurrent chordoma, a rare bone cancer.[40]
• Melanoma: In a subset of patients with metastatic or unresectable melanoma harboring activating mutations in the c−KIT gene, imatinib is considered a rational off-label treatment option.[40]
• Pigmented Villonodular Synovitis (PVNS) / Tenosynovial Giant Cell Tumor: Imatinib has been used as a monotherapy for this rare, benign but locally aggressive tumor of the joints.[40]
• Investigational Research:
• Multiple Sclerosis (MS): Imatinib is being evaluated in a recruiting Phase 2 clinical trial for MS, suggesting its potential utility may extend beyond oncology into diseases with inflammatory or neurodegenerative components.[42]
• Neurofibromatosis Type I: Early research has shown promise for using imatinib to treat progressive plexiform neurofibromas by leveraging its c-KIT inhibitory properties.[14]
• Infectious Diseases: Preclinical data showing activity against certain coronaviruses and Mycobacterium tuberculosis highlight its potential for repurposing in non-cancer indications.[10]

The clinical journey of imatinib validates the "one drug, multiple targets, multiple diseases" concept. Its initial development was singularly focused on Bcr-Abl in CML, but its subsequent approvals for GIST (driven by c-KIT) and MDS/MPD (driven by PDGFR) demonstrate that a drug's true value is defined by its molecular interactions, not by the organ where the cancer originates. This principle has paved the way for modern "basket trials" and provides the scientific rationale for molecular profiling of tumors to identify patients who may benefit from a targeted drug, regardless of their cancer's histologic classification.

Table 4.1: FDA-Approved Indications for Imatinib with Recommended Dosing
Indication	Specific Patient Population	Recommended Daily Dose
Ph+ CML (Chronic Phase)	Adults	400 mg once daily 26
Ph+ CML (Accelerated Phase or Blast Crisis)	Adults	600 mg once daily 26
Ph+ CML	Pediatrics	340 mg/m²/day (once daily or split BID) 26
Ph+ ALL (Relapsed/Refractory)	Adults	600 mg once daily 26
MDS/MPD	Adults with PDGFR gene rearrangements	400 mg once daily 26
Aggressive Systemic Mastocytosis (ASM)	Adults without D816V c-Kit mutation	100 mg or 400 mg once daily 26
HES/CEL	Adults with FIP1L1-PDGFRα fusion kinase	100 mg or 400 mg once daily 26
Dermatofibrosarcoma Protuberans (DFSP)	Adults (unresectable, recurrent, or metastatic)	800 mg (administered as 400 mg twice daily) 26
GIST (Metastatic and/or Unresectable)	Adults with Kit+ GIST	400 mg once daily 26
GIST (Adjuvant Treatment)	Adults following resection of Kit+ GIST	400 mg once daily 26

Section 5: Safety, Tolerability, and Risk Management

5.1. Profile of Adverse Drug Reactions

While imatinib is generally better tolerated than conventional cytotoxic chemotherapy, it is associated with a distinct and extensive profile of adverse reactions. These toxicities are largely a direct consequence of the inhibition of its target kinases (Abl, KIT, PDGFR) in healthy tissues where these pathways play normal physiological roles.

5.1.1. Common and Manageable Side Effects

The most frequently reported adverse reactions, occurring in over 10% of patients, are generally low-grade and manageable. These include:

• Fluid retention (edema): Often presents as periorbital (around the eyes) or lower extremity swelling.
• Gastrointestinal issues: Nausea, vomiting, and diarrhea are very common.
• Musculoskeletal pain: Muscle cramps, myalgia, and arthralgia are frequently reported.
• Fatigue: A common, non-specific side effect.
• Skin rash: Various types of rashes can occur.
• Abdominal pain.[14]

Other common side effects include headache, dizziness, and blurred vision, which may impact activities such as driving.[14]

5.1.2. Serious and Clinically Significant Toxicities

Although less frequent, imatinib can cause severe and potentially life-threatening toxicities that require careful monitoring and management.

• Severe Fluid Retention: This is a hallmark toxicity. It can manifest as more severe conditions such as pleural effusion (fluid around the lungs), pericardial effusion (fluid around the heart), pulmonary edema, and ascites (fluid in the abdomen). The risk is dose-related and is higher in older patients.[26] This effect is thought to be linked to the inhibition of PDGFR, which plays a role in regulating interstitial fluid pressure.
• Cytopenias: Myelosuppression is a common and significant toxicity. This includes anemia (low red blood cells), neutropenia (low neutrophils), and thrombocytopenia (low platelets). The incidence and severity are higher at increased dosages and in patients with advanced-stage disease (accelerated or blast phase CML).[26] This is likely due to the inhibition of c-KIT on hematopoietic progenitor cells.
• Cardiac Toxicity: Cases of severe congestive heart failure and left ventricular dysfunction have been reported, especially in patients with pre-existing cardiac conditions or other risk factors.[17] The inhibition of the Abl kinase in cardiomyocytes is believed to be a contributing mechanism.
• Hepatotoxicity: Severe liver injury, including cases of fatal liver failure, can occur. Regular monitoring of liver function is mandatory.[17]
• Hemorrhage: Grade 3/4 bleeding events have been reported in clinical trials, particularly in patients with GIST or newly diagnosed CML.[26]
• Renal Toxicity: Long-term treatment with imatinib has been associated with a slow but progressive decline in renal function, as measured by the estimated glomerular filtration rate (eGFR).[17] Animal studies at very high doses showed evidence of tubular nephrosis.[34]
• Hypothyroidism: In patients who have undergone a thyroidectomy and are receiving levothyroxine replacement therapy, imatinib can increase the clearance of levothyroxine, leading to hypothyroidism.[26]
• Tumor Lysis Syndrome (TLS): In patients with a high tumor burden, the rapid killing of cancer cells can lead to TLS, a metabolic emergency.[17]

5.2. Contraindications, Warnings, and Precautions

The FDA prescribing information for imatinib includes several important warnings and precautions, some of which are highlighted in a boxed warning.

• Pregnancy: Imatinib is classified as Pregnancy Category D. It has the potential to cause fetal harm when administered to a pregnant woman, and its use should be avoided during pregnancy.[17]
• Contraindications: The primary contraindication is known hypersensitivity to imatinib or any of its components.
• Warnings and Precautions (from FDA Label):
• Fetal Harm: Women of childbearing potential should be advised of the potential harm to the fetus.
• Edema and Severe Fluid Retention: Patients should be weighed regularly. Unexpected rapid weight gain should be managed with diuretics and potential drug interruption.
• Cytopenias: Complete blood counts must be performed regularly. Dose reduction or interruption may be necessary.
• Severe Congestive Heart Failure and Left Ventricular Dysfunction: Patients with cardiac disease or risk factors should be monitored closely.
• Hepatotoxicity: Liver function should be assessed before starting treatment and monitored monthly.
• Hemorrhage: Patients should be monitored for signs of bleeding.[26]

5.3. Management of Adverse Events and Dose Modifications

The management of imatinib-related toxicities is a cornerstone of successful long-term therapy.

• Fluid retention is typically managed with supportive care, including diuretics. In severe cases, imatinib treatment may need to be interrupted.[33]
• Cytopenias are generally managed by either reducing the dose of imatinib or temporarily interrupting therapy until blood counts recover.[26]
• Patients with cardiac disease or risk factors for heart failure require vigilant monitoring and appropriate management of their cardiac condition.[26]
• For laboratory abnormalities such as elevated liver transaminases or bilirubin, or for severe non-hematologic toxicities, the prescribing information provides specific guidelines for dose interruption and/or reduction.
• A structured monitoring schedule is essential: complete blood counts should be checked weekly for the first month, biweekly for the second month, and periodically thereafter. Liver function tests should be performed before initiation and monthly during therapy.[26]

Section 6: Clinically Significant Drug and Food Interactions

The safe use of imatinib requires careful consideration of its extensive potential for drug-drug and drug-food interactions. These interactions are a direct result of its metabolism by and inhibition of the cytochrome P450 enzyme system, making it a central hub for pharmacokinetic interactions.

6.1. Interactions Mediated by CYP450 Enzymes

6.1.1. Impact of CYP3A4 Inhibitors and Inducers on Imatinib Exposure

Imatinib is primarily metabolized by CYP3A4, making its plasma concentration highly susceptible to modulation by other drugs that affect this enzyme.

• CYP3A4 Inhibitors: Co-administration of imatinib with strong inhibitors of CYP3A4 can significantly increase imatinib plasma concentrations and the risk of toxicity. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., clarithromycin), and certain antiviral protease inhibitors (e.g., ritonavir).[8] A clinical study showed that co-administration with ketoconazole increased the imatinib AUC by 40%.[8] Patients must be counseled to avoid these combinations or, if unavoidable, may require a dose reduction of imatinib with close monitoring.
• CYP3A4 Inducers: Conversely, co-administration with strong inducers of CYP3A4 can dramatically decrease imatinib plasma concentrations, potentially leading to a loss of therapeutic efficacy and disease progression. Examples of strong CYP3A4 inducers include certain anticonvulsants (e.g., phenytoin, carbamazepine), rifampin, and the herbal supplement St. John's wort.[25] A study with rifampin demonstrated a 74% decrease in the imatinib AUC, rendering the standard dose sub-therapeutic.[8] Co-administration with strong inducers should be avoided. If it is necessary, a significant increase in the imatinib dose may be required.

6.1.2. Imatinib as an Inhibitor of CYP Enzymes

Imatinib is not only a substrate but also an inhibitor of several key CYP enzymes. It is a moderate inhibitor of CYP3A4 and a potent inhibitor of CYP2D6 and CYP2C9.[1] This means imatinib can increase the plasma concentrations of other drugs that are metabolized by these enzymes, which is particularly dangerous for drugs with a narrow therapeutic index.

• CYP3A4 Substrates: Imatinib can increase levels of co-administered CYP3A4 substrates. A classic example is simvastatin; imatinib increased the AUC of simvastatin by 3.5-fold, significantly increasing the risk of statin-related toxicity.[8]
• CYP2D6 and CYP2C9 Substrates: Caution is required when imatinib is given with substrates of CYP2D6 (e.g., metoprolol) or CYP2C9 (e.g., warfarin).[36]

6.2. Interactions with Other Medications

• Warfarin: The interaction with warfarin is particularly complex and clinically significant. Warfarin is primarily metabolized by CYP2C9, which imatinib inhibits. Co-administration can lead to elevated warfarin levels and an increased risk of serious bleeding.[45] Due to this risk, it is generally recommended that patients requiring anticoagulation be treated with alternative agents, such as low-molecular-weight heparin or standard heparin, instead of warfarin.[46]
• Acetaminophen (Tylenol): There is a potential for imatinib to inhibit the metabolism of acetaminophen, which could increase the risk of acetaminophen-induced liver damage, especially with high doses or chronic use.[47]
• Statins: Imatinib can significantly increase the exposure of several statins, including simvastatin, atorvastatin, and rosuvastatin, by inhibiting their CYP3A4-mediated metabolism. This increases the risk of myopathy and rhabdomyolysis. Dose adjustments of the statin or switching to a statin less dependent on CYP3A4 metabolism may be necessary.[46]

6.3. Food and Herbal Supplement Interactions

Patient education regarding food and supplement interactions is critical for safety.

• Grapefruit Juice: Grapefruit and its juice are potent inhibitors of intestinal CYP3A4. Consumption can lead to significantly increased imatinib plasma levels and a higher risk of adverse effects. Patients must be strictly counseled to avoid all grapefruit products during imatinib therapy.[44]
• St. John's Wort: This popular herbal supplement is a potent inducer of CYP3A4. Its use can drastically reduce imatinib levels, leading to therapeutic failure. Patients must be explicitly warned against taking St. John's wort.[44]
• Other Supplements: Other herbal products, such as pomegranate, black cohosh, and goldenseal, have also been noted to potentially interact with tyrosine kinase inhibitors and should generally be avoided.[51]

A thorough medication reconciliation, including prescription drugs, over-the-counter products, and herbal supplements, is an absolute necessity before initiating and during imatinib therapy. The complexity of these interactions underscores the importance of a multidisciplinary care team involving physicians and pharmacists to ensure patient safety.

Table 6.1: Major Drug and Food Interactions with Imatinib
Interacting Agent/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin)	Inhibition of imatinib metabolism	Increased imatinib plasma concentration; increased risk of toxicity	Avoid co-administration. If necessary, consider reducing imatinib dose with close monitoring. 8
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine)	Induction of imatinib metabolism	Decreased imatinib plasma concentration; risk of therapeutic failure	Avoid co-administration. If necessary, a significant increase in imatinib dose may be required. 8
Grapefruit / Grapefruit Juice	Potent inhibition of intestinal CYP3A4	Increased imatinib plasma concentration; increased risk of toxicity	Strictly avoid consumption during therapy. 45
St. John's Wort	Potent induction of CYP3A4	Decreased imatinib plasma concentration; risk of therapeutic failure	Strictly avoid use during therapy. 44
CYP3A4 Substrates (e.g., Simvastatin, Amlodipine)	Imatinib inhibits CYP3A4	Increased plasma concentration of the substrate drug; increased risk of its specific toxicities	Use with caution. Monitor for toxicity and consider dose reduction of the substrate drug or use of an alternative agent. 32
Warfarin	Imatinib inhibits CYP2C9, the primary metabolizing enzyme for warfarin	Increased warfarin levels; increased risk of bleeding	Avoid co-administration. Use alternative anticoagulants like low-molecular-weight heparin if possible. 45

Section 7: Market Landscape and Future Perspectives

7.1. Commercial History, Branding, and Generic Entry

Imatinib, marketed by Novartis, became a global pharmaceutical phenomenon under the brand names Gleevec in the United States and Glivec in Europe and other regions.[14] It rapidly achieved blockbuster status, with its revolutionary efficacy driving massive commercial success. In 2015, on the eve of its patent expiry in the US, global sales of Gleevec reached $4.66 billion.[52]

The patent expiration paved the way for generic competition. The first generic version of imatinib mesylate was launched in the United States by Sun Pharmaceuticals in February 2016, following FDA approval based on demonstrating bioequivalence to the branded product.[52] Since then, other manufacturers, such as Teva Pharmaceuticals, have also introduced generic versions, increasing market competition.[53] Even after generic entry, the market has seen the introduction of new branded formulations, such as Imkeldi, an oral solution approved in 2024, representing a strategy to serve specific patient populations and maintain a brand presence.[11]

7.2. Cost-Effectiveness and Economic Considerations

The pricing of imatinib has been a focal point of the broader debate on the cost of cancer care. When it was first launched in 2001, the annual price was approximately $26,000.[52] However, over its patent life, the price increased dramatically. By 2016, the wholesale acquisition cost (WAC) for branded Gleevec in the US had soared to over $120,000 per year, and the average wholesale price (AWP) was over $145,000.[52]

The arrival of generics was anticipated to bring significant cost savings. However, the initial impact was muted. Due to market exclusivity provisions granted to the first generic filer under the Hatch-Waxman Act, the first generic from Sun Pharma was launched at a price only modestly lower than the branded drug, not the 30% discount that had been publicized.[52]

Despite the high price, numerous health economic analyses have been conducted. These studies consistently conclude that using lower-cost generic imatinib as the first-line therapy for CML is the most cost-effective strategy. This approach reserves the newer, more expensive second- and third-generation tyrosine kinase inhibitors (such as dasatinib, nilotinib, and ponatinib) for patients who fail or are intolerant to imatinib.[52] The economic lifecycle of imatinib—from a high-priced, paradigm-shifting branded drug to a more affordable generic standard of care—serves as a powerful case study on the tensions between rewarding pharmaceutical innovation, market dynamics, and the societal need for affordable access to life-saving medicines.

7.3. Conclusion: The Enduring Legacy and Future Directions of Imatinib

Imatinib will be remembered as one of the most important medical advances of the early 21st century. It was the agent that proved the principle of targeted cancer therapy, transforming a lethal cancer into a manageable chronic illness and giving hope and years of life to hundreds of thousands of patients worldwide. Its development story is a model of successful translational medicine, showcasing a seamless progression from fundamental biological discovery to rational drug design and definitive clinical validation.

The legacy of imatinib extends far beyond its direct therapeutic benefits. It fundamentally reshaped the landscape of oncology drug discovery, shifting the industry's focus toward molecularly targeted agents. It also ignited a global conversation about the value and cost of innovative medicines that continues to this day.

Looking forward, the story of imatinib is not over. Its role as a cost-effective, first-line therapy for CML and GIST is secure. Furthermore, ongoing research into its utility for non-oncologic conditions like multiple sclerosis and infectious diseases may yet uncover new applications for this remarkable molecule.[10] As cancer therapy moves toward complex combination regimens, imatinib will likely find new roles as a backbone agent. Its journey from a single-target "magic bullet" to a multi-purpose therapeutic tool with a complex economic and social history cements its place as a true landmark in medicine.

Works cited

1. Imatinib | C29H31N7O | CID 5291 - PubChem, accessed July 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Imatinib
2. pubchem.ncbi.nlm.nih.gov, accessed July 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Imatinib#:~:text=It%20is%20a%20N%2Dmethylpiperazine,functionally%20related%20to%20a%20benzamide.&text=Imatinib%20is%20a%20small%20molecule,chronic%20myeloid%20leukemia%2C%20in%202001.
3. Imatinib: A Breakthrough of Targeted Therapy in Cancer - PMC - PubMed Central, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4055302/
4. Off-label use of targeted therapies in oncology - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4826971/
5. Gleevec (imatinib mesylate) FDA Approval History - Drugs.com, accessed July 9, 2025, https://www.drugs.com/history/gleevec.html
6. Imatinib Pathway, Pharmacokinetics/Pharmacodynamics - PharmGKB, accessed July 9, 2025, https://www.pharmgkb.org/pathway/PA164713427
7. Imatinib in Chronic Myeloid Leukemia: an Overview - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3894842/
8. Gleevec - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21335se8-Gleevec_lbl.pdf
9. Imatinib: A Breakthrough of Targeted Therapy in Cancer - PMC, accessed July 9, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055302/
10. imatinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 9, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687
11. Imkeldi (imatinib mesylate) FDA Approval History - Drugs.com, accessed July 9, 2025, https://www.drugs.com/history/imkeldi.html
12. Imatinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 9, 2025, https://go.drugbank.com/drugs/DB00619
13. Imatinib mesylate | STI571 | CAS#220127-57-1 - MedKoo Biosciences, accessed July 9, 2025, https://www.medkoo.com/products/4549
14. Imatinib - Wikipedia, accessed July 9, 2025, https://en.wikipedia.org/wiki/Imatinib
15. Definition of imatinib mesylate - NCI Drug Dictionary, accessed July 9, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
16. Imatinib - Novartis - AdisInsight - Springer, accessed July 9, 2025, https://adisinsight.springer.com/drugs/800006806
17. Imatinib - StatPearls - NCBI Bookshelf, accessed July 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK551676/
18. go.drugbank.com, accessed July 9, 2025, https://go.drugbank.com/drugs/DB00619#:~:text=Imatinib%20is%20a%202%2Dphenylaminopyrimidine,class%20of%20tyrosine%20kinase%20inhibitors.&text=Although%20imatinib%20inhibits%20a%20number,is%20present%20in%20various%20cancers.
19. pubchem.ncbi.nlm.nih.gov, accessed July 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Imatinib#:~:text=Imatinib%20is%20a%20benzamide%20obtained,%2D1%2C3%2Ddiamine.
20. CAS Number 152459-95-5 | Imatinib - Spectrum Chemical, accessed July 9, 2025, https://www.spectrumchemical.com/cas/152459-95-5
21. Gleevec® - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s009lbl.pdf
22. Imatinib free base | STI571 | CAS#152459-95-5 - MedKoo Biosciences, accessed July 9, 2025, https://www.medkoo.com/products/13871
23. KEGG DRUG: Imatinib mesylate, accessed July 9, 2025, https://www.genome.jp/dbget-bin/www_bget?D01441
24. imatinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 9, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=5687
25. Glivec™ (imatinib mesylate) - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21335lbl.pdf
26. GLEEVEC (imatinib mesylate) tablets Label - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
27. www.medkoo.com, accessed July 9, 2025, https://www.medkoo.com/products/13871#:~:text=Imatinib%20is%20a%20tyrosine%20kinase,their%20downstream%20signal%20transduction%20pathways.
28. pmc.ncbi.nlm.nih.gov, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3894842/#:~:text=Imatinib%20binds%20to%20BCR%2DABL,leukemic%20cell%20apoptosis%20is%20induced.
29. Clinical pharmacokinetics of imatinib - PubMed, accessed July 9, 2025, https://pubmed.ncbi.nlm.nih.gov/16122278/
30. imatinib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 9, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=5687
31. Showing BioInteractions for Imatinib (DB00619) | DrugBank Online, accessed July 9, 2025, https://go.drugbank.com/drugs/DB00619/biointeractions
32. 21-335 Gleevec Clinical Pharmacology Biopharmaceutics Review Part 1 - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf
33. iMAtinib - Cancer Care Ontario, accessed July 9, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43866
34. 21-335 Gleevec Pharmacology Review Part 1 - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_pharmr_P1.pdf
35. What to avoid when taking Gleevec? - Drugs.com, accessed July 9, 2025, https://www.drugs.com/medical-answers/avoid-taking-gleevec-3556579/
36. Drugs@FDA: Drug Product Gleevec (imatinib mesylate), NDA021588, Novartis Pharmaceuticals Corporation - PharmGKB, accessed July 9, 2025, https://www.pharmgkb.org/literature/15101892/overview
37. Gleevec, Imkeldi (imatinib) dosing, indications, interactions, adverse ..., accessed July 9, 2025, https://reference.medscape.com/drug/gleevec-imkeldi-imatinib-342239
38. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates - PubMed Central, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3423228/
39. Imatinib Mesylate - NCI, accessed July 9, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate
40. Drug Policy: Gleevec™ (imatinib mesylate), accessed July 9, 2025, https://www.nhpri.org/wp-content/uploads/2022/06/UM-ONC_1177-Gleevec-imatinib-mesylate_05272022.pdf
41. Drug Policy: Gleevec™ (imatinib mesylate), accessed July 9, 2025, https://www.nhpri.org/wp-content/uploads/2021/12/UM-ONC_1177-Gleevec-imatinib-mesylate_11292021.pdf
42. Multiple Sclerosis Recruiting Phase 2 Trials for Imatinib (DB00619) | DrugBank Online, accessed July 9, 2025, https://go.drugbank.com/indications/DBCOND0027885/clinical_trials/DB00619?phase=2&status=recruiting
43. highlights of prescribing information - accessdata.fda.gov, accessed July 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021588s020lbl.pdf
44. Imatinib: MedlinePlus Drug Information, accessed July 9, 2025, https://medlineplus.gov/druginfo/meds/a606018.html
45. What To Avoid When Taking Gleevec — Plus, 6 More Pharmacist-Backed Tips for Taking It, accessed July 9, 2025, https://www.goodrx.com/imatinib/what-to-avoid-when-taking-gleevec
46. 7 Imatinib Interactions You Should Know About - GoodRx, accessed July 9, 2025, https://www.goodrx.com/imatinib/interactions
47. Gleevec interactions: Supplements, alcohol, and more - Medical News Today, accessed July 9, 2025, https://www.medicalnewstoday.com/articles/drugs-gleevec-interactions
48. www.goodrx.com, accessed July 9, 2025, https://www.goodrx.com/imatinib/interactions#:~:text=Imatinib%20may%20increase%20blood%20levels,Rosuvastatin%20(Crestor)
49. Gleevec and Alcohol/Food Interactions - Drugs.com, accessed July 9, 2025, https://www.drugs.com/food-interactions/imatinib,gleevec.html
50. Imatinib (oral route) - Mayo Clinic, accessed July 9, 2025, https://www.mayoclinic.org/drugs-supplements/imatinib-oral-route/description/drg-20068331
51. Drug & Food Interactions - National CML Society, accessed July 9, 2025, https://www.nationalcmlsociety.org/drug-food-interactions
52. Generic imatinib — impact on frontline and salvage therapy for CML - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5450934/
53. Imatinib Mesylate Tablets - Teva Pharmaceuticals USA, accessed July 9, 2025, https://www.tevausa.com/our-products/tevagenerics/teva-generics-catalog/vision-product-page/imatinibmesylatetablets